Study of Acalabrutinib (ACP-196) in combination with Venetoclax (ABT-199), with and without Obinutuzumab (GA101) versus Chemoimmunotherapy for Previously Untreated CLL - AMPLIFY

Study identifier:ACE-CL-311

ClinicalTrials.gov identifier:NCT03836261

EudraCT identifier:2018-002443-28

CTIS identifier:N/A

Recruitment Complete

Official Title

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation (AMPLIFY)

Medical condition

Chronic Lymphocytic Leukemia

Phase

Phase 3

Healthy volunteers

Study drug

Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab

Sex

All

Actual Enrollment

984

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Feb 2019

Estimated Primary Completion Date: 06 Jan 2027

Estimated Study Completion Date: 06 Jan 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by AcertaPharma

Collaborators

AstraZeneca

Inclusion and exclusion criteria

Inclusion Criteria

• Men and women ≥18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0–2.
• Diagnosis of CLL that meets published diagnostic criteria (Hallek et al. 2018)
• Active disease per IWCLL 2018 criteria that requires treatment.
• Participants must use highly effective birth control throughout the study.

Exclusion Criteria

• Any prior CLL-specific therapies.
• Detected del(17p) or TP53 mutation.
• Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (e.g., Richter’s transformation, prolymphocytic leukemia [PLL], or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia.
• History of confirmed progressive multifocal leukoencephalopathy (PML).
• Received any investigational drug within 30 days before first dose of study drug.
• Major surgical procedure within 30 days before the first dose of study drug.
• Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study.
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
• Received a live virus vaccination within 28 days of first dose of study drug.
• Known history of infection with human immunodeficiency virus (HIV).
• Serologic status reflecting active hepatitis B or C infection.
• History of known hypersensitivity or anaphylactic reactions to study drugs or excipients.
• History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
• Known bleeding disorders.
• Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
• Female participants must not be breastfeeding or pregnant.
• Concurrent participation in another therapeutic clinical trial.

No locations available

Arms	Assigned Interventions
Experimental: Acalabrutinib, Venetoclax Acalabrutinib in combination with Venetoclax	Drug: Acalabrutinib Acalabrutinib, Other Name: Calquence (acalabrutinib) Drug: Venetoclax Venetoclax Other Name: Venclyxto, Venclexta
Experimental: Acalabrutinib, Venetoclax, Obinutuzumab Acalabrutinib in combination with Venetoclax with Obinutuzumab	Drug: Acalabrutinib Acalabrutinib, Other Name: Calquence (acalabrutinib) Drug: Venetoclax Venetoclax Other Name: Venclyxto, Venclexta Drug: Obinutuzumab Obinutuzumab Other Name: Gazyva, Gazyvaro
Active Comparator: Chemoimmunotherapy Chemoimmunotherapy FCR: Fludarabine, Cyclophosphamide and Rituximab BR: Bendamustine and Rituximab	Drug: Chemoimmunotherapy fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Jennifer Brown

Dana Farber Mass General Brigham Cancer Care Inc